CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvantedbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00742885
NCT00742885Phase 2Completed
CompareCT.gov

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.

GlaxoSmithKline·interventional·Posted Aug 28, 2008·Updated Aug 20, 2018

In Brief

A Phase 2 clinical trial evaluating Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted for Influenza. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 28, 2008
Enrollment StartSep 1, 2008
Primary CompletionMar 7, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.8 years ago

Interventions

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvantedbiological

All subjects will receive 2 doses administered as an intramuscular (IM) injection.